

## Supplementary Data

**TABLE S1.** Details of the most common AEs, all SAEs, and all AEs considered possibly related to study treatment.

|  | <b>CHC<br/>(n = 8)</b>                    |                             | <b>Placebo<br/>(n = 8)</b>                |                             |
|--|---|-----------------------------|---|-----------------------------|
|  | <b>Number<br/>of<br/>patients<br/>(%)</b> | <b>Number<br/>of events</b> | <b>Number<br/>of<br/>patients<br/>(%)</b> | <b>Number<br/>of events</b> |
| AEs occurring in $\geq 2$ patients/group |   |                             |   |                             |
| Hypertension                             | 5 (63)                                    | 5                           | 2 (25)                                    | 2                           |
| Anemia                                   | 5 (63)                                    | 5                           | 2 (25)                                    | 2                           |
| Urinary tract infection                  | 1 (13)                                    | 1                           | 4 (50)                                    | 4                           |
| Hyperkalemia <sup>a</sup>                | 3 (38)                                    | 4                           | 0   | 0                           |
| Nausea                                   | 3 (38)                                    | 3                           | 1 (13)                                    | 1                           |
| Condition aggravated                     | 2 (25)                                    | 2                           | 1 (13)                                    | 1                           |
| Dyspepsia                                | 1 (13)                                    | 1                           | 2 (25)                                    | 2                           |
| Insomnia                                 | 2 (25)                                    | 2                           | 1 (13)                                    | 1                           |
| Alanine aminotransferase                 | 0   | 0                           | 2 (25)                                    | 2                           |

|  |        |   |        |   |
|--|--------|---|--------|---|
| increased                              |        |   |        |   |
| Amylase increased                      | 2 (25) | 2 | 0      | 0 |
| Diabetes mellitus                      | 0      | 0 | 2 (25) | 2 |
| Diarrhea                               | 2 (25) | 2 | 0      | 0 |
| Pruritus                               | 2 (25) | 2 | 0      | 0 |
| Thrombocytopenia                       | 2 (25) | 2 | 0      | 0 |
| Any SAE                                |        |   |        |   |
| Urosepsis                              | 1 (13) | 1 | 1 (13) | 1 |
| Postprocedural hemorrhage <sup>b</sup> | 1 (13) | 1 | 0      | 0 |
| Urinary retention                      | 0      | 0 | 1 (13) | 1 |
| AE possibly related to study treatment |        |   |        |   |
| Anemia                                 | 1 (13) | 1 | 0      | 0 |
| Oral fungal infection                  | 0      | 0 | 1 (13) | 1 |
| Postprocedural hemorrhage <sup>b</sup> | 1 (13) | 1 | 0      | 0 |
| Hematoma                               | 1 (13) | 2 | 0      | 0 |

<sup>a</sup>Blood potassium increase was noted in one further patient in the CHC group and one patient in the placebo group.

<sup>b</sup>Postprocedural hemorrhage occurred in one patient and was classified as an SAE and also as an AE possibly related to study treatment.

AE, adverse event; CHC, Corline Heparin Conjugate; SAE, serious adverse event.

**TABLE S2.** CHC uptake per kidney derived from the CHC concentration left in the preservation solution.

| <b>Patient number</b> | <b>Kidney weight, g</b> | <b>CHC uptake, mg</b> | <b>CHC uptake per 100 g kidney weight, mg/100 g</b> |
|-----------------------|-------------------------|-----------------------|---|
| 102                   | 246                     | 23                    | 9   |
| 103                   | 170                     | 52                    | 31  |
| 105                   | 316                     | 25                    | 8   |
| 701                   | 239                     | 22                    | 9   |
| 702                   | 267                     | 21                    | 8   |
| 108                   | 339                     | 48                    | 14  |
| 202                   | 275                     | 22                    | 8   |
| 109                   | 281                     | 28                    | 10  |

CHC, Corline Heparin Conjugate.